Article
REAL-WORLD EFFECTIVENESS OF NIRMATRELVIR/RITONAVIR ON COVID-19-ASSOCIATED HOSPITALIZATION PREVENTION: A POPULATION-BASED COHORT STUDY IN THE PROVINCE OF QUÉBEC, CANADA
2023-02-22
Abstract excerpt
<h4>ABSTRACT</h4> <h4>Introduction</h4> The nirmatrelvir/ritonavir (PAXLOVID™) is an antiviral blocking the replication of SARS-CoV-2. Early treatment with this antiviral has showed to reduce COVID-19 hospitalization and death in unvaccinated outpatients with mild-to-moderate COVID-19 and high risk of progression to severe disease with variants before Omicron. However, the current epidemiological context and the l...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 1f2ca9b3-6a26-5300-a720-1541561dee36
- DOI
- 10.1101/2023.02.14.23285860
